Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ - PubMed
3 months ago
- #nonsurgical management
- #DCIS
- #breast cancer
- Active surveillance is emerging as a strategy to reduce overtreatment in low-risk ductal carcinoma in situ (DCIS).
- The study analyzed trends in nonsurgical management for low-risk, hormone receptor-positive DCIS from 2004 to 2022.
- Nonsurgical management increased from 2.1% to 3.5%, while lumpectomy plus adjuvant radiotherapy decreased from 50.9% to 45.6%.
- Bilateral mastectomy increased from 4.1% to 8.7%, more common among younger, White, and privately insured patients.
- Endocrine therapy use peaked in 2020 but declined afterward, with highest use after lumpectomy plus adjuvant radiotherapy (69.6%).
- Socioeconomic disparities were noted, with nonsurgical management more common among Black patients and those without insurance.
- Precision-based, patient-centered care is emphasized for individualized treatment strategies in low-risk DCIS.